[1] Chang YJ, Huang XJ. Donor lymphocyte infusions for relapse after allogeneic transplantation. When, if and for whom? Blood Rev, 2013, 27: 55-62. [2] Takeuchi A, Eto M, Tatsugami K, et al. Renal cancer treatment with recipient lymphocyte infusion enhanced the anti-tumor effect of nonmyeloablative allogeneic stem cell transplantation. Transpl Immunol, 2015, 32: 131-139. [3] 苏毅,范方毅,易海,等. 化疗联合半相合供者淋巴细胞输注治疗难治性非霍奇金淋巴瘤实验及临床研究.西南国防医药,2010, 20: 1070-1073. [4] Schirrmacher V. Complete remission of cancer in late-stage disease by radiation and transfer of allogeneic MHC-matched immune T cells: lessons from GvL studies in animals. Cancer Immunol Immunother, 2014, 63: 535-543. [5] van Bergen CA, Verdegaal EM, Honders MW,et al. Durable remission of renal cell carcinoma in conjuncture with graft versus host disease following allogeneic stem cell transplantation and donor lymphocyte infusion: rule or exception. PLoS One, 2014, 9: e85198. [6] Baek HJ, Han DK, Hwang TJ, et al. Long-term graft-versus-tumor effect following reduced intensity hematopoietic stem cell transplantation in a child with metastatic renal cell carcinoma. Pediatr Blood Cancer, 2012, 59: 583-585. [7] Chen Q, Lin RB, Ye YB, et al. The combined administration of partially HLA-matched irradiated allogeneic lymphocytes and thalidomide in advanced renal-cell carcinoma: a case report. Med Oncol, 2010, 27: 554-558. [8] 汤志伟,李洁羽,彭峰,等.环磷酰胺联合照射后半相合淋巴细胞对小鼠肝癌移植瘤的抑制作用.中国肿瘤生物治疗杂志,2012,19: 45-51. [9] 苏晓三,张蕾,伍尚敏,等.灭活同种异基因白细胞输注抗肿瘤转移的研究.中华肿瘤防治杂志,2010,17: 991-994. [10] 武汉,王金成,张春秋,等. 纤维蛋白胶与异种骨复合支架中立体培养的免骨髓基质细胞. 中国组织工程研究与临床康复,2009,13: 3016-3019. [11] 陈继凤,彭江,张莉,等.生物蛋白胶作为骨髓间充质干细胞移植载体的体外相容性研究.中国矫形外科杂志,2012,20: 1424-1427. [12] 艾军,白引苗,李巧霞,等. CIK体内外抗宫颈HeLa细胞的作用及其荷瘤小鼠体内分布特点.中国肿瘤生物治疗杂志, 2012,19: 374-380. [13] 徐兵,吴林岚,杨晓梅,等.B超引导下肝包膜下骨髓间充质干细胞移植治疗大鼠肝损伤.肝脏,2014,19: 604-606. |